$CLVT

Cornick Kenneth L. purchased $1.7M of CLVT (indirect holdings)

Cornick Kenneth L. purchased 900,000 indirectly-held shares of CLARIVATE PLC (CLVT) at an average of $1.86 ($1.85–$1.86, $1.67M total) across 2 trades over 2026-08-06 to 2026-08-07.

Original reporting
SEC EDGAR · Cornick Kenneth L.
Published Aug 10, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLVT
Bullish
medium confidence
Mentioned
$CLVT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLVTBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase of 900,000 shares (indirect holdings) at $1.8500 to $1.8600 per share, totaling $1.6715M, reported via Form 4 filed 2026-08-10.

02

Market read

Traders may treat the insider buy as a small sentiment input, but there is no accompanying fundamental update in the text.

03

What to watch

The filing notes no 10b5-1 plan, but it also provides no rationale for the purchase, and the trades occurred days before the filing, reducing immediacy.

Relevance 7/10Novelty 5/10Timing: Form 4 filed 2026-08-10 after trades dated 2026-08-06 to 2026-08-07

Background

The article is a SEC Form 4 insider transaction disclosure for Clarivate PLC (CLVT).

Company-level read

Ticker impact

$CLVTBullishMedium confidence
Context

Clarivate PLC director Cornick Kenneth L. bought 900,000 shares in open-market trades for about $1.67M, filed as a Form 4 on 2026-08-10.

Expected impact

Likely limited near-term impact; any effect is typically small and short-lived versus macro or company-specific fundamentals.

Evidence & confidence

The filing is a primary-source Form 4 and the transaction size is non-trivial, but the article provides no new company performance, outlook, or regulatory/contract event that would drive repricing.

Market effects

No sector-wide implications are disclosed; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine (tax planning, diversification, or pre-existing intent) and may not reflect a change in fundamentals.

Key entities

  • CLARIVATE PLC

    Subject of the Form 4 insider transaction disclosure.

  • Cornick Kenneth L.

    Director who purchased 900,000 shares in open-market trades (indirect holdings).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLVTMed

Clarivate Completes Sale of Life Sciences & Healthcare Segment, Advances Strategic Transformation

Clarivate (NYSE: CLVT) completed the $600M sale of its Life Sciences & Healthcare segment to Altaris, simplifying its portfolio and focusing on Academia & Government and Intellectual Property segments. The company plans to use proceeds to reduce debt and strengthen its balance sheet, aiming to drive growth and shareholder value. Clarivate will update its full-year 2026 guidance on November 3, 2026.